PBE Fees and Costs — Invesco Biotechnology & Genome ETF
Data updated: 2026-09-28
The net expense ratio is 0.59%: a 0.50% management fee plus 0.09% other expenses. There are no sales loads or redemption fees. In fiscal 2026 the fund paid $150K in broker commissions, 0.0625% of average net assets, and portfolio turnover was 103%.
PBE Fees and Expenses
Annual operating expenses and sales charges of PBE. Prospectus, as of August 27, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 0.50% |
| 12b-1 fee | — |
| Other expenses | 0.09% |
| Gross expense ratio | 0.59% |
| Fee waiver | — |
| Net expense ratio | 0.59% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | Yes |
PBE Costs Over Time
On $10,000 invested in PBE, assuming 5% a year before costs, total costs come to $411 over 5 years, cutting the return by 0.69% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.59%) | $62 | $194 | $338 |
| Trading costs (broker commissions) | $7 | $21 | $36 |
| Lost growth on money paid in costs | $0 | $11 | $38 |
| Total costs | $69 | $225 | $411 |
| Value after costs | $10,431 | $11,351 | $12,352 |
| Impact on return, per year | 0.69% | 0.69% | 0.69% |
PBE Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending April 30, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.0625%
- Total broker commissions: $150K
- Bought from dealers (principal trades, not a cost): $61.8M
- Portfolio turnover (prospectus): 103%
- Securities on loan, average value: $30.9M
- Net income from securities lending: $355K (0.148% of average net assets)
PBE Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| INVESCO CAPITAL MARKETS, INC. | $67K | 44.83% |
| MORGAN STANLEY & CO. LLC | $35K | 23.56% |
| BARCLAYS CAPITAL INC. | $24K | 16.12% |
| RBC CAPITAL MARKETS, LLC | $21K | 13.91% |
| TD Securities (USA) LLC | $2K | 1.24% |
| CITIGROUP GLOBAL MARKETS INC. | $271 | 0.18% |
| MIZUHO SECURITIES USA LLC | $165 | 0.11% |
| UBS SECURITIES LLC | $47 | 0.03% |
| WELLS FARGO SECURITIES, LLC | $25 | 0.02% |
| MERRILL LYNCH, PIERCE, FENNER & SMITH INC. | $13 | 0.01% |
PBE Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| CITADEL SECURITIES LLC | $24.3M | 39.27% |
| BNY MELLON CAPITAL MARKETS, LLC | $10.0M | 16.11% |
| MERRILL LYNCH, PIERCE, FENNER & SMITH INC. | $9.6M | 15.47% |
| RBC CAPITAL MARKETS, LLC | $7.2M | 11.71% |
| GOLDMAN, SACHS & CO. | $5.2M | 8.34% |
| VIRTU AMERICAS LLC | $3.2M | 5.15% |
| HRT Financial LP | $1.7M | 2.72% |
| UBS SECURITIES LLC | $701K | 1.13% |
| WELLS FARGO SECURITIES, LLC | $67K | 0.11% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.